327 related articles for article (PubMed ID: 21375467)
1. Genotoxicity of retroviral hematopoietic stem cell gene therapy.
Trobridge GD
Expert Opin Biol Ther; 2011 May; 11(5):581-93. PubMed ID: 21375467
[TBL] [Abstract][Full Text] [Related]
2. Stem cell gene therapy: the risks of insertional mutagenesis and approaches to minimize genotoxicity.
Wu C; Dunbar CE
Front Med; 2011 Dec; 5(4):356-71. PubMed ID: 22198747
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy for inherited immunodeficiency.
Touzot F; Hacein-Bey-Abina S; Fischer A; Cavazzana M
Expert Opin Biol Ther; 2014 Jun; 14(6):789-98. PubMed ID: 24823313
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for PIDs: progress, pitfalls and prospects.
Mukherjee S; Thrasher AJ
Gene; 2013 Aug; 525(2):174-81. PubMed ID: 23566838
[TBL] [Abstract][Full Text] [Related]
5. Parachuting in the epigenome: the biology of gene vector insertion profiles in the context of clinical trials.
Baum C
EMBO Mol Med; 2011 Feb; 3(2):75-7. PubMed ID: 21254403
[TBL] [Abstract][Full Text] [Related]
6. Ten years of gene therapy for primary immune deficiencies.
Aiuti A; Roncarolo MG
Hematology Am Soc Hematol Educ Program; 2009; ():682-9. PubMed ID: 20008254
[TBL] [Abstract][Full Text] [Related]
7. Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial.
Wang GP; Berry CC; Malani N; Leboulch P; Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Bushman FD
Blood; 2010 Jun; 115(22):4356-66. PubMed ID: 20228274
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy for severe combined immunodeficiencies and beyond.
Fischer A; Hacein-Bey-Abina S
J Exp Med; 2020 Jan; 217(2):. PubMed ID: 31826240
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy of primary T cell immunodeficiencies.
Fischer A; Hacein-Bey-Abina S; Cavazzana-Calvo M
Gene; 2013 Aug; 525(2):170-3. PubMed ID: 23583799
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy for X-Linked Severe Combined Immunodeficiency: Where Do We Stand?
Cavazzana M; Six E; Lagresle-Peyrou C; André-Schmutz I; Hacein-Bey-Abina S
Hum Gene Ther; 2016 Feb; 27(2):108-16. PubMed ID: 26790362
[TBL] [Abstract][Full Text] [Related]
11. Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy.
Davé UP; Akagi K; Tripathi R; Cleveland SM; Thompson MA; Yi M; Stephens R; Downing JR; Jenkins NA; Copeland NG
PLoS Genet; 2009 May; 5(5):e1000491. PubMed ID: 19461887
[TBL] [Abstract][Full Text] [Related]
12. Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.
Ferrua F; Aiuti A
Hum Gene Ther; 2017 Nov; 28(11):972-981. PubMed ID: 28847159
[TBL] [Abstract][Full Text] [Related]
13. A possible turning point in the hematopoietic stem cell gene therapy for primary immunodeficiency diseases? Lentiviral vectors could take the place of retroviral vectors.
Ariga T
Expert Rev Clin Immunol; 2013 Nov; 9(11):1015-8. PubMed ID: 24168409
[TBL] [Abstract][Full Text] [Related]
14. Retrovirus-induced oncogenesis and safety of retroviral vectors.
Nair V
Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials.
Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM
Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239
[TBL] [Abstract][Full Text] [Related]
16. Gene Therapies for Primary Immune Deficiencies.
Kohn LA; Kohn DB
Front Immunol; 2021; 12():648951. PubMed ID: 33717203
[TBL] [Abstract][Full Text] [Related]
17. Gene Therapy Approaches to Immunodeficiency.
Ghosh S; Gaspar HB
Hematol Oncol Clin North Am; 2017 Oct; 31(5):823-834. PubMed ID: 28895850
[TBL] [Abstract][Full Text] [Related]
18. Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype correction independent of insertional mutagenesis and gammac overexpression.
Ginn SL; Liao SH; Dane AP; Hu M; Hyman J; Finnie JW; Zheng M; Cavazzana-Calvo M; Alexander SI; Thrasher AJ; Alexander IE
Mol Ther; 2010 May; 18(5):965-76. PubMed ID: 20354504
[TBL] [Abstract][Full Text] [Related]
19. Sola dosis facit venenum. Leukemia in gene therapy trials: a question of vectors, inserts and dosage?
Staal FJ; Pike-Overzet K; Ng YY; van Dongen JJ
Leukemia; 2008 Oct; 22(10):1849-52. PubMed ID: 18769449
[TBL] [Abstract][Full Text] [Related]
20. Genotoxicity assay for gene therapy vectors in tumor prone Cdkn2a⁻/⁻ mice.
Montini E; Cesana D
Methods Enzymol; 2012; 507():171-85. PubMed ID: 22365774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
